Breaking News

Financial Report: Johnson & Johnson

July 15, 2014

Revenues up 9% in the quarter driven by new products

Johnson & Johnson
2Q Revenues: $19.5 billion (+9%)

2Q Earnings: $4.3 billion (+13%)

YTD Revenues: $37.6 billion (+6%)

YTD Earnings: $9.1 billion (+24%)

Comments: Pharmaceutical sales were $8.5 billion, up 21%, with domestic sales up 37% and international sales up 7%. Growth was primarily driven by new products including OLYSIO/SOVRIAD (simeprevir), for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; ZYTIGA for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA for type 2 diabetes; and IMBRUVICA for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Sales were negatively impacted by loss of exclusivity for ACIPHEX for gastrointestinal disorders, and CONCERTA, an ADHD treatment.